In last trading session, Prime Medicine Inc (NASDAQ:PRME) saw 0.56 million shares changing hands with its beta currently measuring 1.86. Company’s recent per share price level of $2.80 trading at -$0.03 or -1.06% at ring of the bell on the day assigns it a market valuation of $367.26M. That closing price of PRME’s stock is at a discount of -248.93% from its 52-week high price of $9.77 and is indicating a premium of 8.57% from its 52-week low price of $2.56. Taking a look at company’s average trading volume for last 10-days demonstrates a volume of 0.75 million shares which gives us an average trading volume of 1.09 million if we extend that period to 3-months.
For Prime Medicine Inc (PRME), analysts’ consensus is at an average recommendation of Buy while assigning it a mean rating of 1.20. Splitting up the data highlights that, out of 5 analysts covering the stock, 0 rated the stock as a Sell while 0 recommended an Overweight rating for the stock. 1 suggested the stock as a Hold whereas 4 see the stock as a Buy. 0 analyst(s) advised it as an Underweight. The company is expected to be making an EPS of -0.31 in the current quarter.
Prime Medicine Inc (NASDAQ:PRME) trade information
Upright in the red during last session for losing -1.06%, in the last five days PRME remained trading in the red while hitting it’s week-highest on Monday, 01/27/25 when the stock touched $2.80 price level, adding 15.15% to its value on the day. Prime Medicine Inc’s shares saw a change of -4.11% in year-to-date performance and have moved -11.11% in past 5-day. Prime Medicine Inc (NASDAQ:PRME) showed a performance of 0.72% in past 30-days. Number of shares sold short was 17.21 million shares which calculate 15.18 days to cover the short interests.
Wall Street analysts have assigned a consensus price target of 17 to the stock, which implies a rise of 83.53% to its current value. Analysts have been projecting 12 as a low price target for the stock while placing it at a high target of 23. It follows that stock’s current price would drop -328.57% in reaching the projected high whereas dropping to the targeted low would mean a loss of -328.57% for stock’s current value.
Prime Medicine Inc (PRME) estimates and forecasts
Statistics highlight that Prime Medicine Inc is scoring comparatively higher than the scores of other players of the relevant industry. The company lost -50.09% of value to its shares in past 6 months, showing an annual growth rate of 17.24% while that of industry is 16.00. Apart from that, the company came raising its revenue forecast for fiscal year 2025.
9 industry analysts have given their estimates about the company’s current quarter revenue by setting an average figure of 5.81M for the same. And 6 analysts are in estimates of company making revenue of 3.79M in the next quarter.
Weighing up company’s earnings over the past 5-year and in the next 5-year periods, we find the company posting an annual earnings growth rate of -193.88% during past 5 years. In 2025, company’s earnings growth rate is likely to be around 26.60% while estimates for its earnings growth in next 5 years are of 20.17%.
Prime Medicine Inc (NASDAQ:PRME)’s Major holders
Insiders are in possession of 23.91% of company’s total shares while institution are holding 62.40 percent of that, with stock having share float percentage of 82.00%. Investors also watch the number of corporate investors in a company very closely, which is 62.40% institutions for Prime Medicine Inc that are currently holding shares of the company.
On the other hand, ARK ETF Tr-ARK Genomic Revolution ETF and ARK ETF Tr-ARK Innovation ETF are the top two Mutual Funds which own company’s shares. As of Nov 30, 2024 , the former fund manager was holding 2.63 shares of worth $7.36 million or 2.00% of the total outstanding shares. The later fund manager was in possession of 2.36 shares on Nov 30, 2024 , making its stake of worth around $6.62 million in the company or a holder of 1.80% of company’s stock.
